I arrived in Chicago the day before the start of the 103rd Annual Meeting of the American Association for Cancer Research (AACR), filled with anticipation. I was feeling very lucky to be selected again to participate in AACR’s Scientist - Survivor Program, whose goal is to build bridges and unity among the leaders of the scientific and cancer survivor and patient advocacy communities worldwide.
Use of neoadjuvant sipuleucel-T (Provenge) engendered an immune response in men with early-stage prostate cancer slated for radical prostatectomy (RP), according to a study presented at a poster session at the 2012 American Society of Clinical Oncology Genitourinary Cancers Symposium held in San Francisco, California. The vaccine is approved by the US Food and Drug Administration in the setting of rising prostate-specific antigen (PSA) level in metastatic castration-resistant prostate cancer, and this study suggests that it may be beneficial when used up front. Read More ›
Ginseng has significant activity against fatigue in adults with cancer, according to a randomized trial.1 Eight weeks of treatment with ginseng significantly improved fatigue scores by 20% versus 10% for patients treated with placebo (P = .003). Moreover, ginseng was as safe as placebo in this preliminary trial.
ASCO’s Quality Oncology Practice Initiative (QOPI), an oncology-led, quality assessment and improvement program, measured family history taking and genetic counseling/testing practices among 750 community oncology practices. Results of this study revealed gaps that need to be addressed in making sure the taking of family history is accurate and patients whose cancers may have a heritable component get referred for genetic counseling and testing. Read More ›
To sign up for our newsletter or print publications, please enter your contact information below.
